2.94 USD
▼-0.02-0.68%
盘后 3.36 0.00%
2026-11-20
市值
$306.34M
市盈率
—
EPS
-0.66
股息率
—
52 周区间
2.43 – 4.83
成交量
1.39M
Beta
0.47
目标价
11.60
52W 低 2.4352W 高 4.83
价格走势
公司简介
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Ta...